ParkinsonFranceV1, Hal, Curation, bibRecord, 000638

Mechanism of CDK5/p25 binding by CDK inhibitors

Identifieur interne : 000638 ( Hal/Curation ); précédent : 000637; suivant : 000639

Mechanism of CDK5/p25 binding by CDK inhibitors

Auteurs : M. Mapelli ; L. Massimiliano ; C. Crovace ; Seeliger M. A. ; Tsai L. H. ; L. Meijer [France] ; A. Musacchio

Source :

Journal of Medicinal Chemistry [ 0022-2623 ] ; 2005.

RBID : Hal:hal-00018754

Abstract

The cyclin-dependent kinases (CDK) CDK1, CDK2, CDK4, and CDK6 are serine/threonine protein kinases targeted in cancer therapy due to their role in cell cycle progression. The postmitotic CDK5 is involved in biological pathways important for neuronal migration and differentiation. CDK5 represents an attractive pharmacological target as its deregulation is implicated in various neurodegenerative diseases such as Alzheimer's, Parkinson's, and Niemann-Pick type C diseases, ischemia, and amyotrophic lateral sclerosis. We have generated an improved crystal form of CDK5 in complex with p25, a segment of the p35 neuronal activator. The crystals were used to solve the structure of CDK5/p25 with (R)-roscovitine and aloisine at a resolution of 2.2 and 2.3 A, respectively. The structure of CDK5/p25/roscovitine provides a rationale for the preference of CDK5 for the R over the S stereoisomer. Furthermore, roscovitine stabilized an unusual collapsed conformation of the glycine-rich loop, an important site of CDK regulation, and we report an investigation of the effects of glycine-rich loop phosphorylation on roscovitine binding. The CDK5/p25 crystals represent a valuable new tool for the identification and optimization of selective CDK inhibitors.

Url:

https://hal.archives-ouvertes.fr/hal-00018754

Links toward previous steps (curation, corpus...)

to stream Hal, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000702

Links to Exploration step

Hal:hal-00018754

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mechanism of CDK5/p25 binding by CDK inhibitors</title>
<author><name sortKey="Mapelli, M" sort="Mapelli, M" uniqKey="Mapelli M" first="M." last="Mapelli">M. Mapelli</name>
</author>
<author><name sortKey="Massimiliano, L" sort="Massimiliano, L" uniqKey="Massimiliano L" first="L." last="Massimiliano">L. Massimiliano</name>
</author>
<author><name sortKey="Crovace, C" sort="Crovace, C" uniqKey="Crovace C" first="C." last="Crovace">C. Crovace</name>
</author>
<author><name sortKey="M A, Seeliger" sort="M A, Seeliger" uniqKey="M A S" first="Seeliger" last="M. A.">Seeliger M. A.</name>
</author>
<author><name sortKey="L H, Tsai" sort="L H, Tsai" uniqKey="L H T" first="Tsai" last="L. H.">Tsai L. H.</name>
</author>
<author><name sortKey="Meijer, L" sort="Meijer, L" uniqKey="Meijer L" first="L." last="Meijer">L. Meijer</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-1838" status="VALID">  <orgName>Molécules et cibles thérapeutiques</orgName>
  <orgName type="acronym">MCT</orgName>
  <desc>    <address>      <addrLine>Station biologique Place Georges Teissier - BP 74 29682 ROSCOFF CEDEX</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
  <listRelation>    <relation name="UPS2682" active="#struct-441569" type="direct"></relation>
  </listRelation>
<tutelles><tutelle name="UPS2682" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"><idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc><address><country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Musacchio, A" sort="Musacchio, A" uniqKey="Musacchio A" first="A." last="Musacchio">A. Musacchio</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-00018754</idno>
<idno type="halId">hal-00018754</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-00018754</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-00018754</idno>
<date when="2005">2005</date>
<idno type="wicri:Area/Hal/Corpus">000702</idno>
<idno type="wicri:Area/Hal/Curation">000702</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Mechanism of CDK5/p25 binding by CDK inhibitors</title>
<author><name sortKey="Mapelli, M" sort="Mapelli, M" uniqKey="Mapelli M" first="M." last="Mapelli">M. Mapelli</name>
</author>
<author><name sortKey="Massimiliano, L" sort="Massimiliano, L" uniqKey="Massimiliano L" first="L." last="Massimiliano">L. Massimiliano</name>
</author>
<author><name sortKey="Crovace, C" sort="Crovace, C" uniqKey="Crovace C" first="C." last="Crovace">C. Crovace</name>
</author>
<author><name sortKey="M A, Seeliger" sort="M A, Seeliger" uniqKey="M A S" first="Seeliger" last="M. A.">Seeliger M. A.</name>
</author>
<author><name sortKey="L H, Tsai" sort="L H, Tsai" uniqKey="L H T" first="Tsai" last="L. H.">Tsai L. H.</name>
</author>
<author><name sortKey="Meijer, L" sort="Meijer, L" uniqKey="Meijer L" first="L." last="Meijer">L. Meijer</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-1838" status="VALID">  <orgName>Molécules et cibles thérapeutiques</orgName>
  <orgName type="acronym">MCT</orgName>
  <desc>    <address>      <addrLine>Station biologique Place Georges Teissier - BP 74 29682 ROSCOFF CEDEX</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
  <listRelation>    <relation name="UPS2682" active="#struct-441569" type="direct"></relation>
  </listRelation>
<tutelles><tutelle name="UPS2682" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID"><idno type="IdRef">02636817X</idno>
<idno type="ISNI">0000000122597504</idno>
<orgName>Centre National de la Recherche Scientifique</orgName>
<orgName type="acronym">CNRS</orgName>
<date type="start">1939-10-19</date>
<desc><address><country key="FR"></country>
</address>
<ref type="url">http://www.cnrs.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Musacchio, A" sort="Musacchio, A" uniqKey="Musacchio A" first="A." last="Musacchio">A. Musacchio</name>
</author>
</analytic>
<series><title level="j">Journal of Medicinal Chemistry</title>
<idno type="ISSN">0022-2623</idno>
<imprint><date type="datePub">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The cyclin-dependent kinases (CDK) CDK1, CDK2, CDK4, and CDK6 are serine/threonine protein kinases targeted in cancer therapy due to their role in cell cycle progression. The postmitotic CDK5 is involved in biological pathways important for neuronal migration and differentiation. CDK5 represents an attractive pharmacological target as its deregulation is implicated in various neurodegenerative diseases such as Alzheimer's, Parkinson's, and Niemann-Pick type C diseases, ischemia, and amyotrophic lateral sclerosis. We have generated an improved crystal form of CDK5 in complex with p25, a segment of the p35 neuronal activator. The crystals were used to solve the structure of CDK5/p25 with (R)-roscovitine and aloisine at a resolution of 2.2 and 2.3 A, respectively. The structure of CDK5/p25/roscovitine provides a rationale for the preference of CDK5 for the R over the S stereoisomer. Furthermore, roscovitine stabilized an unusual collapsed conformation of the glycine-rich loop, an important site of CDK regulation, and we report an investigation of the effects of glycine-rich loop phosphorylation on roscovitine binding. The CDK5/p25 crystals represent a valuable new tool for the identification and optimization of selective CDK inhibitors.</div>
</front>
</TEI>
<hal api="V3">          <titleStmt>            <title xml:lang="en">Mechanism of CDK5/p25 binding by CDK inhibitors</title>
            <author role="aut">              <persName>                <forename type="first">M.</forename>
                <surname>Mapelli</surname>
              </persName>
              <idno type="halauthorid">82019</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">L.</forename>
                <surname>Massimiliano</surname>
              </persName>
              <idno type="halauthorid">82020</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">C.</forename>
                <surname>Crovace</surname>
              </persName>
              <idno type="halauthorid">82021</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">Seeliger</forename>
                <surname>M. A.</surname>
              </persName>
              <idno type="halauthorid">82022</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">Tsai</forename>
                <surname>L. H.</surname>
              </persName>
              <idno type="halauthorid">82023</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">L.</forename>
                <surname>Meijer</surname>
              </persName>
              <idno type="halauthorid">86404</idno>
              <affiliation ref="#struct-1838"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">A.</forename>
                <surname>Musacchio</surname>
              </persName>
              <idno type="halauthorid">82024</idno>
            </author>
            <editor role="depositor">              <persName>                <forename>Sophie</forename>
                <surname>Paris</surname>
              </persName>
              <email type="md5">e9ec0424cf0251493f3c05d8eac22a2a</email>
              <email type="domain">sb-roscoff.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>            <edition n="v1" type="current">              <date type="whenSubmitted">2006-02-08 16:36:51</date>
              <date type="whenModified">2006-02-08 16:36:51</date>
              <date type="whenReleased">2006-02-08 16:36:51</date>
              <date type="whenProduced">2005</date>
            </edition>
            <respStmt>              <resp>contributor</resp>
              <name key="107282">                <persName>                  <forename>Sophie</forename>
                  <surname>Paris</surname>
                </persName>
                <email type="md5">e9ec0424cf0251493f3c05d8eac22a2a</email>
                <email type="domain">sb-roscoff.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>            <distributor>CCSD</distributor>
            <idno type="halId">hal-00018754</idno>
            <idno type="halUri">https://hal.archives-ouvertes.fr/hal-00018754</idno>
            <idno type="halBibtex">mapelli:hal-00018754</idno>
            <idno type="halRefHtml">Journal of Medicinal Chemistry, American Chemical Society, 2005, 48, pp.671-679</idno>
            <idno type="halRef">Journal of Medicinal Chemistry, American Chemical Society, 2005, 48, pp.671-679</idno>
          </publicationStmt>
          <seriesStmt>            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
          </seriesStmt>
          <notesStmt>            <note type="audience" n="1">Not set</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>            <biblStruct>              <analytic>                <title xml:lang="en">Mechanism of CDK5/p25 binding by CDK inhibitors</title>
                <author role="aut">                  <persName>                    <forename type="first">M.</forename>
                    <surname>Mapelli</surname>
                  </persName>
                  <idno type="halauthorid">82019</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">L.</forename>
                    <surname>Massimiliano</surname>
                  </persName>
                  <idno type="halauthorid">82020</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">C.</forename>
                    <surname>Crovace</surname>
                  </persName>
                  <idno type="halauthorid">82021</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Seeliger</forename>
                    <surname>M. A.</surname>
                  </persName>
                  <idno type="halauthorid">82022</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Tsai</forename>
                    <surname>L. H.</surname>
                  </persName>
                  <idno type="halauthorid">82023</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">L.</forename>
                    <surname>Meijer</surname>
                  </persName>
                  <idno type="halauthorid">86404</idno>
                  <affiliation ref="#struct-1838"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">A.</forename>
                    <surname>Musacchio</surname>
                  </persName>
                  <idno type="halauthorid">82024</idno>
                </author>
              </analytic>
              <monogr>                <idno type="halJournalId" status="VALID">15785</idno>
                <idno type="issn">0022-2623</idno>
                <idno type="eissn">1520-4804</idno>
                <title level="j">Journal of Medicinal Chemistry</title>
                <imprint>                  <publisher>American Chemical Society</publisher>
                  <biblScope unit="volume">48</biblScope>
                  <biblScope unit="pp">671-679</biblScope>
                  <date type="datePub">2005</date>
                </imprint>
              </monogr>
            </biblStruct>
          </sourceDesc>
          <profileDesc>            <langUsage>              <language ident="en">English</language>
            </langUsage>
            <textClass>              <classCode scheme="halDomain" n="sdv.bbm">Life Sciences [q-bio]/Biochemistry, Molecular Biology</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">The cyclin-dependent kinases (CDK) CDK1, CDK2, CDK4, and CDK6 are serine/threonine protein kinases targeted in cancer therapy due to their role in cell cycle progression. The postmitotic CDK5 is involved in biological pathways important for neuronal migration and differentiation. CDK5 represents an attractive pharmacological target as its deregulation is implicated in various neurodegenerative diseases such as Alzheimer's, Parkinson's, and Niemann-Pick type C diseases, ischemia, and amyotrophic lateral sclerosis. We have generated an improved crystal form of CDK5 in complex with p25, a segment of the p35 neuronal activator. The crystals were used to solve the structure of CDK5/p25 with (R)-roscovitine and aloisine at a resolution of 2.2 and 2.3 A, respectively. The structure of CDK5/p25/roscovitine provides a rationale for the preference of CDK5 for the R over the S stereoisomer. Furthermore, roscovitine stabilized an unusual collapsed conformation of the glycine-rich loop, an important site of CDK regulation, and we report an investigation of the effects of glycine-rich loop phosphorylation on roscovitine binding. The CDK5/p25 crystals represent a valuable new tool for the identification and optimization of selective CDK inhibitors.</abstract>
          </profileDesc>
        </hal>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Hal/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000638 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Hal/Curation/biblio.hfd -nk 000638 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Hal
   |étape=   Curation
   |type=    RBID
   |clé=     Hal:hal-00018754
   |texte=   Mechanism of CDK5/p25 binding by CDK inhibitors
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Mechanism of CDK5/p25 binding by CDK inhibitors

Mechanism of CDK5/p25 binding by CDK inhibitors

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri